Context Therapeutics Inc.
CNTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001842952
No open-market purchases or sales by Context Therapeutics Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $34.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +21 vs. previous quarter
- 79
- 13F valueReported value at the end of Q2 2026
- $34.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CNTX, Q2 2026
No superinvestor reported holding CNTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Context Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Lehr Martin A.Chief Executive Officer | PPurchase | +100.0K | $0.70 | +$70.0K | +12.2%920.2K after | |
| Jun 10, 2025 (view filing) | Jun 6 | 4 days | Levit Alex C.Chief Legal Officer, Corp. Sec | PPurchase | +20.0K | $0.58 | +$11.6K | +222.2%29.0K after | |
| Jun 10, 2025 (view filing) | Jun 6 | 4 days | Minai-Azary Jennifer LynnChief Financial Officer | PPurchase | +40.0K | $0.64 | +$25.6K | +100.0%80.0K after | |
| Feb 21, 2023 (view filing) | Feb 21 | Same day | Lehr Martin A.Chief Executive Officer | PPurchase | +5.82K | $0.84 | +$4.89K | +3.8%159.7K after | |
| Feb 13, 2023 (view filing) | Feb 13 | Same day | Lehr Martin A.Chief Executive Officer | PPurchase | +5.61K | $0.87 | +$4.88K | +3.8%153.9K after | |
| Feb 6, 2023 (view filing) | Feb 6 | Same day | Lehr Martin A.Chief Executive Officer | PPurchase | +5.04K | $0.97 | +$4.89K | +3.5%148.3K after | |
| Jan 30, 2023 (view filing) | Jan 30 | Same day | Lehr Martin A.Chief Executive Officer | PPurchase | +7.03K | $0.70 | +$4.92K | +5.2%143.2K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Lehr Martin A.Chief Executive Officer | PPurchase | +6.84K | $0.72 | +$4.92K | +5.3%136.2K after | |
| Jan 18, 2023 (view filing) | Jan 17 | 1 day | Lehr Martin A.Chief Executive Officer | PPurchase | +6.78K | $0.74 | +$5.02K | +5.5%129.4K after | |
| Dec 19, 2022 (view filing) | Dec 16 | 3 days | Minai-Azary Jennifer LynnChief Financial Officer | PPurchase | +25.0K | $0.74 | +$18.5K | +166.7%40.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Context Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 7,419,355 | $4.11M | 0.20% | 00.0% | Unchanged |
| Deep Track Capital, LP | 7,419,355 | $4.11M | 0.06% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 7,063,141 | $3.91M | 0.13% | +100,000+1.4% | Added |
| BlackRock, Inc. | 6,169,250 | $3.42M | 0.00% | +5,322,554+628.6% | Added |
| Avidity Partners Management LP | 4,998,267 | $2.77M | 0.44% | −4,998,267−50.0% | Reduced |
| Franklin Resources Inc | 3,803,338 | $2.11M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 3,432,052 | $1.90M | 0.00% | +990.0% | Added |
| Octagon Capital Advisors LP | 3,050,000 | $1.69M | 0.16% | −2,200,000−41.9% | Reduced |
| Blue Owl Capital Holdings LP | 2,934,015 | $1.63M | 0.25% | −2,155,000−42.3% | Reduced |
| TCG Crossover Management, LLC | 2,682,696 | $1.49M | 0.04% | 00.0% | Unchanged |